|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Treatment of locally advanced rectal cancer:Controversies and questions显示文摘Rectal cancers extending through the rectal wall, or involving locoregional lymph nodes (T3/4 or N1/2), have been more difficult to cure. The confines of the bony pelvis and the necessity of preserving the autonomic nerves makes surgical extirpation challenging, which accounts for the high rates of local and distant relapse in this setting. Combined multimodality treatment for rectal cancer stage Ⅱ and Ⅲ was recommended from National Institute of Health consensus. Neoadjuvant chemoradiation using fluoropyrimidine-based regimen prior to surgical resection has emerged as the standard of care in the United States. Optimal time of surgery after neoadjuvant treatment remained unclear and prospective randomized controlled trial is ongoing. Traditionally, 6-8 wk waiting period was commonly used. The accuracy of studies attempting to determine tumor complete response remains problematic. Currently, surgery remains the standard of care for rectal cancer patients following neoadjuvant chemoradiation, where-as observational management is still investigational. In this article, we outline trends and controversies associated with optimal pre-treatment staging, neoadjuvant therapies, surgery, and adjuvant therapy. | Atthaphorn Trakarnsanga Suthinee Ithimakin Martin R Weiser | 2012 | World Journal of Gastroenterology2012，18，39： | 5 |
| 2 | Predictive significance of cancer related-inflammatory markers in locally advanced rectal cancer显示文摘BACKGROUND Locally advanced rectal cancer is treated using neoadjuvant chemoradiation(nCRT),followed by total mesorectal excision(TME).Tumor regression and pathological post-treatment stage are prognostic for oncological outcomes.There is a significant correlation between markers representing cancer-related inflammation,including high neutrophil-to-lymphocyte ratio(NLR),monocyteto-lymphocyte ratio(MLR),and platelet-to-lymphocyte(MLR)and unfavorable oncological outcomes.However,the predictive role of these markers on the effect of chemoradiation is unknown.AIM To evaluate the predictive roles of NLR,MLR,and PLR in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiation.METHODS Patients(n=111)with locally advanced rectal cancer who underwent nCRT followed by TME at the Minimally Invasive Surgery Unit,Siriraj Hospital between 2012 and 2018 were retrospectively analyzed.The associations between post-treatment pathological stages,neoadjuvant rectal(NAR)score and the pretreatment ratios of markers of inflammation(NLR,MLR,and PLR)were analyzed.RESULTS Clinical stages determined using computed tomography,magnetic resonance imaging,or both were T4(n=16),T3(n=94),and T2(n=1).The NAR scores were categorized as high(score>16)in 23.4%,intermediate(score 8-16)in 41.4%,and low(score<8)in 35.2%.The mean values of the NLR,PLR,and MLR correlated with pathological tumor staging(ypT)and the NAR score.The values of NLR,PLR and MLR were higher in patients with advanced pathological stage and high NAR scores,but not statistically significant.CONCLUSION In patients with locally advanced rectal cancer,pretreatment NLR,MLR and PLR are higher in those with advanced pathological stage but the differences are not significantly different. | Kitinat Timudom Thawatchai Akaraviputh Vitoon Chinswangwatanakul Ananya Pongpaibul Pornpim Korpraphong Janjira Petsuksiri Suthinee Ithimakin Atthaphorn Trakarnsanga | 2020 | World Journal of Gastrointestinal Surgery2020，12，9： | 3 |
| 3 | Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population显示文摘 | Hasan Korkaya Gwang-il Kim April Davis Fayaz Malik N. Lynn Henry Suthinee Ithimakin Ahmed A. Quraishi Nader Tawakkol Rosemarie D’Angelo Amanda K. Paulson Susan Chung Tahra Luther Hayley J. Paholak Suling Liu Khaled A. Hassan Qin Zen Shawn G. Clouthier Max | 2012 | Molecular Cell2012，，4： | 1 |
| 4 | Cancer anemia survey in Division of Medical Oncology at Siriraj Hospital ( CAS ) 显示文摘 | Ithimakin S Srimuninnimit V | 2009 | J Med Assoc Thai2009，92，2： | 1 |
| 5 | HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implica- tions for efficacy of adjuvant trastuzumab 显示文摘 | Ithimakin S Day KC Malik F | 2013 | Cancer Res2013，73，5： | 1 |
| 6 | Cancer Anemia Survey in Division of Medical Oneology at Siriarj Hospital(CAS)显示文摘 | Suthinee Ithimakin MD | 2009 | J Med Assoc Thai2009，92，2： | 1 |
| 7 | Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexa- methasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice显示文摘 | Ithimakin S Runglodvatana K Nimmannit A | 2012 | Support Care Cancer2012，20，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员